Stocktoria

GRAIL, Inc. GRAL

Nasdaq · stock · Services-Medical Laboratories · website · IPO 2024-06-12 · LEI

GRAIL, Inc. financials (annual)

Revenue
$93.1M $125.6M $147.2M 202320242025
Net income
-$1.47B -$2.03B -$408.4M 202320242025
Free cash flow
-$608.7M -$582.4M -$299.9M 202320242025

Bars are annual figures from 2023 to 2025; red bars are negative (a loss or cash outflow).

MetricFY2025FY2024FY2023
Revenue$147.2M$125.6M$93.1M
R&D expense$195.8M$322.4M$338.7M
Operating income-$562.2M-$2.2B-$1.5B
Income tax-$126.2M-$135.4M-$42.0M
Net income-$408.4M-$2.0B-$1.5B
EPS (diluted)$-11.11$-63.54$-47.21
Operating cash flow-$299.0M-$577.2M-$595.8M
Free cash flow-$299.9M-$582.4M-$608.7M
Cash & equivalents$249.7M$214.2M$97.3M
Total assets$2.9B$3.0B$3.9B
Total liabilities$344.2M$479.9M$267.6M
Shareholders' equity$2.6B$2.5B

Growth · year-over-year · Revenue CAGR 25.7%

MetricFY2025FY2024FY2023
Revenue growth+17.2%+34.9%

Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.